Skip to main content

. 1954 Nov 6;2(4896):1088–1089. doi: 10.1136/bmj.2.4896.1088

Phenylbutazone and Renal Function

B McDougall Johnson, Ian Mortimer Larkin

PMCID: PMC2079839 PMID: 13199388

1088

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

BERSHOF E., OXMAN A. C. Agranulocytosis following use of phenylbutazone (butazolidin). J Am Med Assoc. 1953 Feb 14;151(7):557–558. doi: 10.1001/jama.1953.02940070023007b. [DOI] [PubMed] [Google Scholar]
CUDKOWICZ L., JACOBS J. H. Phenylbutazone (butazolidine) in the treatment of chronic arthritis. Lancet. 1953 Jan 31;1(6753):223–224. doi: 10.1016/s0140-6736(53)90891-5. [DOI] [PubMed] [Google Scholar]
ETESS A. D., JACOBSON A. S. Fatality due to agranulocytosis following use of phenylbutazone (butazolidin). J Am Med Assoc. 1953 Feb 21;151(8):639–640. doi: 10.1001/jama.1953.02940080039009. [DOI] [PubMed] [Google Scholar]
GREEN J., WILLIAMS P. O. Effect of butazolidine on the excretion of water and electrolytes. Lancet. 1953 Mar 21;1(6760):575–577. doi: 10.1016/s0140-6736(53)91698-5. [DOI] [PubMed] [Google Scholar]
HINZ C., LAMONT-HAVERS R. W., COMINSKY B., GAINES L. M. Agranulocytosis following use of phenylbutazone (butazolidin); report of a case. J Am Med Assoc. 1953 Jan 3;151(1):38–39. doi: 10.1001/jama.1953.02940010040009. [DOI] [PubMed] [Google Scholar]
STIFEL J. L., BURNHEIMER J. C. Agranulocytosis following administration of phenylbutazone (butazolidin). J Am Med Assoc. 1953 Feb 14;151(7):555–556. doi: 10.1001/jama.1953.02940070021007. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES